ClinicalTrials.gg
RecruitingNCT07225946KLK2-PASengerUpdated Nov 3, 2026

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 3 interventional study of Pasritamig and Docetaxel in Prostatic Neoplasms, Castration-Resistant, sponsored by Janssen Research & Development, LLC. Recruiting at 165 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Nov 3, 2026Study completion moved13 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson — 3 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · Johnson & Johnson.

Planned enrollment
2nd of 10
800 · median 77
Started
2025
with 1 other
Phase 3
3 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 3, and was the 10th registered.

Prostatic Neoplasms, Castration-Resistant

85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

3 of the 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Prostatic Neoplasms, Castration-Resistant by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or death due to any cause) when compared to treatment with docetaxel in participants with metastatic castrate-resistant prostate cancer (mCRPC; a cancer of prostate, a male reproductive gland found below the bladder, that grows despite low levels of male hormones).

03

Conditions studied

  • Prostatic Neoplasms, Castration-Resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed adenocarcinoma of the prostate
  • Have disease that is at the time of screening by computed tomography (CT) or magnetic resonance imaging (MRI) and 99m\^Tc bone scan as determined by the investigator
  • Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to (\<=) 50 nanogram per deciliter (ng/dL) (\<= 1.73 nanomoles per Liter [nmol/L]) at screening
  • Have progressed by PSA or CT/MRI or 99m\^Tc bone scan on at least 1 novel androgen receptor pathway inhibition (ARPI) but no more than 2 different ARPI for any stage of disease. Must have discontinued ARPI before randomization into the study
  • Have an (ECOG) performance status of 0 to 1

Exclusion criteria

Exclusion criteria:

  • Known history of either brain or prostate cancer
  • Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or
  • Prior or concurrent second (other than the disease under study)
  • Received cytotoxic chemotherapy for prostate cancer in any setting
  • Received prior treatment with human kallikrein 2 (KLK-2) directed therapies
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Pasritamig+Docetaxel

    Participants will receive pasritamig along with docetaxel until the end of treatment (EOT) visit or until radiographic disease progression is confirmed by blinded independent central review (BICR), or any other protocol defined criteria are met.

    Drug: Pasritamig · Drug: Docetaxel

  • Active comparator
    Docetaxel

    Participants will receive docetaxel along with prednisone/prednisolone as background medication.

    Drug: Docetaxel · Drug: Prednisone/Prednisolone

Interventions

  • Pasritamig will be administered.

    Also known as: JNJ-78278343

  • Docetaxel will be administered.

  • DrugPrednisone/Prednisolone

    Drug pages: Prednisone · Prednisolone

    Prednisone/Prednisolone will be administered.

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-Free Survival (rPFS) by computed tomography (CT)/magnetic resonance imaging (MRI) or bone scan Assessed by Blinded Independent Central Review (BICR)

    rPFS by CT/MRI or bone scan is assessed by BICR and is defined as the time from the date of randomization to the first date of radiographic disease progression, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 1 years 10 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Up to approximately 4 years 5 months

  2. Time to Symptomatic Progression (TSP)

    TSP is defined as the time from the date of randomization to the date of the first occurrence of any of the following: the use of external beam radiation to relieve cancer-related symptoms, the need for tumor-related surgical intervention, other cancer-related procedures, cancer-related morbid events, and initiation of a new systemic anticancer therapy because of cancer symptoms.

    Time frame: Up to approximately 4 years 5 months

  3. Time to Subsequent Therapy (TST)

    TST is defined as time from randomization to the initiation of any subsequent systemic anticancer therapy for prostate cancer

    Time frame: Up to approximately 4 years 5 months

  4. Time to Skeletal-Related Event (TSRE)

    TSRE is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): the use of external beam radiation therapy to relieve skeletal symptoms, the need for tumor-related orthopedic surgical intervention, the occurrence of new bone fractures (cancer-related; vertebral or non-vertebral) or the occurrence of tumor-related spinal cord compression.

    Time frame: Up to approximately 4 years 5 months

  5. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants who have measurable disease at baseline and have complete response (CR) or partial response (PR) or better by objective radiographic disease evaluation per response evaluation criteria in solid tumors (RECIST) version.1.1 response criteria and no bone progression as per prostate cancer working group 3 (PCWG3) as determined by the BICR.

    Time frame: Up to approximately 4 years 5 months

  6. Duration of Response (DOR)

    DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 4 years 5 months

  7. Time to Prostate-Specific Antigen (PSA) Progression

    Time to PSA progression is defined as the time from randomization to the first date of documented PSA progression per prostate cancer working group 3 (PCWG3) criteria. PSA progression is defined as: (1) After a decline from baseline, PSA increases greater than or equal to (\>=) 25% and \>=2 nanogram per milliliter (ng/mL) above the nadir, confirmed by a second value \>=3 weeks later (that is, a confirmed rising trend), or (2) If there is no decline from baseline, PSA increases \>=25% and \>=2 ng/mL from baseline after 12 weeks

    Time frame: Up to approximately 4 years 5 months

  8. Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 50 Response

    PSA-50 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 50% from baseline, confirmed by a second value, at least 3 weeks apart.

    Time frame: Up to approximately 4 years 5 months

  9. Proportion of Participants Who Achieved Prostate-Specific Antigen (PSA) 90 Response

    PSA-90 response is defined as the proportion of participants with a reduction in blood concentration of PSA (ng/mL) to 90% from baseline, confirmed by a second value, at least 3 weeks apart.

    Time frame: Up to approximately 4 years 5 months

  10. Duration of PSA Response

    Duration of a PSA response is the time taken to achieve a PSA response that is decrease in PSA from baseline by \>= 50%.

    Time frame: Baseline and up to approximately 4 years 5 months

  11. Progression Free Survival After Subsequent Therapy (PFS2)

    PFS2 is defined as the time from randomization to the date of progression (radiographic, clinical, or PSA progression) on the first subsequent anti-cancer (second progression), or death from any cause, whichever comes first.

    Time frame: Up to approximately 4 years 5 months

  12. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An SAE: results in death, is life-threatening, requires inpatient hospitalization or prolonging hospitalization, results in disability, is a congenital birth defect, is a suspected transmission of any infectious agent via a medicinal product, is indicating suicidal ideation, is medically important. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE.

    Time frame: Up to approximately 4 years 5 months

  13. Number of Participants With Clinical Laboratory Abnormalities

    Participants with laboratory abnormalities (hematology, serum chemistry, coagulation, and tumor markers) will be reported.

    Time frame: Up to approximately 4 years 5 months

  14. Change from Baseline in Health Related Quality of Life (HRQoL) as Assessed by Brief Pain Inventory-Short Form (BPI-SF)

    The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain.

    Time frame: Baseline up to approximately 4 years 5 months

  15. Change from Baseline in HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cancer Module (EORTC QLQ-C30) Scale Score

    The EORTC QLQ-C30 - Version 3 is a self-administered, 30-item questionnaire measuring the health-related quality of life of participants with cancer. EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), a global health status / quality of life scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". A high score for a functional scale represents a high level of functioning, whereas a high score for a symptom scale/single item represents a high level of symptom.

    Time frame: Baseline up to approximately 4 years 5 months

  16. Change from Baseline in HRQoL as Assessed by EORTC Quality of Life Questionnaire-Prostate (EORTC QLQ-PR25) Scale Score

    The EORTC QLQ-PR25 is a self-completed instrument was specifically designed for prostate cancer patients and includes 25 items that cover 6 dimensions: (1) PR URI (urinary symptoms, 8 items), (2) PR BOW (bowel symptoms, 4 items), (3) PR HTR (hormonal treatment-related symptoms, 6 items), (4) PR AID (incontinence aid, 1 item), (5) PR SAC (sexually active, 2 items); and (6) PR SFU (sexual function, 4 items). Higher scores on symptom domains (for example., urinary, bowel, etc.) indicate greater symptom burden and higher scores on function domains (for example, Sexual Function) indicate better functioning.

    Time frame: Baseline up to approximately 4 years 5 months

  17. Change from Baseline in HRQoL as Assessed by European Quality of Life Visual Analog Scale (EQ-5D VAS) Score

    The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D includes a visual analog scale (EQ-VAS) that has endpoints labeled "best imaginable health state" and "worst imaginable health state" anchored at 100 and 0, respectively. Here, higher score indicates better quality of life.

    Time frame: Baseline up to approximately 4 years 5 months

  18. Time to Sustained Worsening of Pain as Assessed by BPI-SF

    Time to sustained worsening of pain will be reported using BPI-SF. The BPI-SF was developed to measure both intensity or severity of pain and pain interference with daily life dimensions. It measures pain intensity via 4 questions, that is, "pain at its worst in the last 24 hours", "pain at its least in the last 24 hours", "pain on the average", and "pain you have right now". The BPI-SF assesses how much pain has interfered with the following 7 activities: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. Higher score indicates more pain.

    Time frame: Up to approximately 4 years 5 months

  19. Treatment Side Effect as Assessed by EORTC IL46 Score

    The EORTC IL46 is a single question that assesses bother (burden) of treatment. It is rated on a scale from 1 to 4, ranging from "not at all" to "very much".

    Time frame: Up to approximately 4 years 5 months

  20. European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) Scale Score

    The EQ-5D descriptive system comprises 5 items across the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L uses a 5-point Likert response scale ranging from "No problems" to "Extreme problems". Here, higher score indicates better quality of life.

    Time frame: Up to approximately 4 years 5 months

07

Study locations

165 of 165 sites recruiting

Showing the first 100 of 165 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.

Completion moved once since we started tracking on Sep 25, 2026: Jul 2029 → Jun 2030, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2025
First posted
Nov 10, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Nov 19, 2027
CompletionEst.
Jun 7, 2030was Jul 2029
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added
Show 13 added (12 United States, 1 China)
  • Ronald Reagan UCLA Medical Center · Los Angeles, United States
  • AdventHealth Porter Oncology Research · Denver, United States
  • Massachusetts General · Boston, United States
  • Duke University Medical Center · Durham, United States
  • Prairie Lakes Health Care System · Watertown, United States
  • Renovatio Clinical · The Woodlands, United States
  • Highlands Oncology Group · Springdale, United States
  • Memorial Cancer Institute · Pembroke Pines, United States
  • Center for Cancer and Blood Disorders · Bethesda, United States
  • Cooper Health System MD Anderson Cancer Center at Cooper · Camden, United States
  • Gabrail Cancer Center · Canton, United States
  • Metrohealth Medical Center · Cleveland, United States
  • Peking University First Hospital · Beijing, China
across 2 updates, Sep 25, 2026 – Nov 3, 2026
Study completion
Jul 20, 2029→Jun 7, 2030
Sep 25, 2026
Show all 2 updates
  1. Nov 3, 2026
    7 sites added
    Show 7 added (6 United States, 1 China)
    • Highlands Oncology Group · Springdale, United States
    • Memorial Cancer Institute · Pembroke Pines, United States
    • Center for Cancer and Blood Disorders · Bethesda, United States
    • Cooper Health System MD Anderson Cancer Center at Cooper · Camden, United States
    • Gabrail Cancer Center · Canton, United States
    • Metrohealth Medical Center · Cleveland, United States
    • Peking University First Hospital · Beijing, China
    + 1 other change: verification date
  2. Sep 25, 2026
    6 sites added
    Show 6 added (6 United States)
    • Ronald Reagan UCLA Medical Center · Los Angeles, United States
    • AdventHealth Porter Oncology Research · Denver, United States
    • Massachusetts General · Boston, United States
    • Duke University Medical Center · Durham, United States
    • Prairie Lakes Health Care System · Watertown, United States
    • Renovatio Clinical · The Woodlands, United States
    Study completion Jul 20, 2029→Jun 7, 2030
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07225946
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Dec 19, 2025
Primary completion
Nov 19, 2027 (estimated)
Completion
Jun 7, 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pasritamig

Start the discussion